EU/3/15/1533: Orphan designation for the treatment of osteogenesis imperfecta
Human allogeneic bone-marrow-derived osteoblastic cells
Table of contents
Overview
On 10 August 2015, orphan designation (EU/3/15/1533) was granted by the European Commission to Bone Therapeutics SA, Belgium, for human allogeneic bone-marrow-derived osteoblastic cells for the treatment of osteogenesis imperfecta.
Key facts
Active substance |
Human allogeneic bone-marrow-derived osteoblastic cells
|
Intended use |
Treatment of osteogenesis imperfecta
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/15/1533
|
Date of designation |
10/08/2015
|
Sponsor |
BioSenic |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Update history
Date | Update |
---|---|
December 2022 | The sponsor’s name was changed from Bone Therapeutics SA to BioSenic and the address was updated. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: